الفهرس 
INTRODUCTION &AIM OF THE WORKOnly 14 pages are availabe for public view
 |  | from | 208 |  |  |
| | | from | 208 | | |
Abstract
In this study we evaluated the efficacy and safety of low-dose
continuous (metronomic) maintenance chemotherapy in patients with
high-risk DLBCL. All these patients achieved complete response to
first- line standard chemotherapy.
The study included 40 patients with high risk diffuse large B-cell
Non Hodgkin lymphoma ((IPI 3, 4, 5) who enrolled to receive oral
high-dose Celecoxib tab 400mg p.o. bid daily,oral low-dose
Cyclophosphamide tab 50mg daily and Methotrexate tab 2.5mg p.o.
1x2 per day, 2 days weekly. This regimen was received for one year.
In this study, maintenance chemotherapy resulted in one year
relapse-free survival rate of 72.5%. The median actuarial Relapse-free
survival was 10.850 months (95% CI, 10.11-11.58).
In our study ,the metronomic chemotherapy regimen was well
tolerated with a low incidence of hematological, gastrointestinal and
renal toxicities.
We concluded that metronomic maintenance can be used for
patients with high-risk DLBCL with reasonable outcome. We
suggested it as an effective and safe treatment with acceptable
toxicity.it is an
.